Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
65 hedge funds and large institutions have $78.1M invested in Zynerba Pharmaceuticals, Inc in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 13 closing their positions.
99% more call options, than puts
Call options by funds: $4.21M | Put options by funds: $2.11M
85% more capital invested
Capital invested by funds: $42.1M → $78.1M (+$36M)
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
3% less funds holding
Funds holding: 67 → 65 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$12.5M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$6.46M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.72M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.68M |
| 5 |
Millennium Management
New York
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$6.08M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$617K |
| 3 |
Squarepoint
New York
|
-$527K |
| 4 |
Goldman Sachs
New York
|
-$280K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$210K |
ZYNE Hedge Fund Activity: Q2 2021 in Review
65 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2021, worth a combined $78.1M — up 85% from $42.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ZYNE and 11 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 24 added.
The largest buyer was ETF Managers Group, adding an estimated $12.5M. The largest seller was AdvisorShares Investments, cutting an estimated $6.08M.
- 65 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2021, down from 67 in Q1 2021.
- Funds reported $78.1M of Zynerba Pharmaceuticals, Inc stock for Q2 2021, up 85% quarter-over-quarter.
- 11 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2021 and 13 closed out, a net change of -2 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2021 was ETF Managers Group, an estimated $12.5M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2021 was AdvisorShares Investments, an estimated $6.08M sold.
Based on aggregated 13F filings for Q2 2021.